New diabetes data from Amylin

Tue, 03 Jun 2008
Amylin Pharmaceuticals will present fresh data on diabetes drugs including Byetta and Symlin, not to mention pipeline diabetes and obesity drug candidates. The data will be revealed at the annual Scientific Sessions put on by the American Diabetes Association.

Health care professionals involved in diabetes research and treatment come from all over the world to the ADA meetings. Amylin has gathered information resources and will present their findings orally and using posters. Amylin will present two symposia focused on multi-hormonal treatment of diabetes and obesity .

The president and CEO of Amylin, Daniel Bradbury, was reported as commenting: "We are excited to demonstrate advancement in our diabetes and obesity pipeline programs at this year's ADA, particularly with updated data related to the once-weekly formulation of exenatide and the combination therapy program for obesity. At Amylin, we continually strive toward our mission of Challenging Science and Changing Lives. By challenging science we question conventional thinking, and open the door for truly innovative approaches for developing novel, life-changing therapies. This unique approach, paired with our deep expertise in peptide hormones and broad experience in diabetes markets, has allowed us to continue developing important medicines with life-changing therapeutic potential for patients."
Leave a Comment
Login via Facebook, Yahoo! and Hotmail
or
Have your full say in the Diabetes Forum
Your comments may be moderated. Please report any spam, illegal, offensive or libellous posts.